Evidence map›Paper›PMID 25541468›Full record

ArticleChemico-biological interactions2015

Aldose reductase expression as a risk factor for cataract.

Anson Snow, Biehuoy Shieh, Kun-Che Chang, Arttatrana Pal, Patricia Lenhart, David Ammar, Philip Ruzycki, Suryanarayana Palla, G Bhanuprakesh Reddy, J Mark Petrash

Abstract read
In one paragraph

Article in Chemico-biological interactions, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Are cinnamon derivatives effective and safe for diabetes?Turkish journal of medical sciences · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Current Approach to the Pathogenesis of Diabetic Cataracts.International journal of molecular sciences · 2023
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. The Protective Effect of Metformin Use on Early Nd:YAG Laser Capsulotomy.Investigative ophthalmology & visual science · 2021
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Anson SnowDepartment of Ophthalmology, University of Colorado Denver, CO, USA.
Biehuoy ShiehDepartment of Ophthalmology, University of Colorado Denver, CO, USA.
Kun-Che ChangDepartment of Ophthalmology, University of Colorado Denver, CO, USA.
Arttatrana PalDepartment of Ophthalmology, University of Colorado Denver, CO, USA.
Patricia LenhartDepartment of Ophthalmology, University of Colorado Denver, CO, USA.
David AmmarDepartment of Ophthalmology, University of Colorado Denver, CO, USA.
Philip RuzyckiDepartment of Ophthalmology, Rocky Mountain Lions Eye Institute, University of Colorado Denver, Aurora, CO, USA.
Suryanarayana PallaBiochemistry Division, National Institute of Nutrition, Hyderabad 500 604, India.
G Bhanuprakesh ReddyBiochemistry Division, National Institute of Nutrition, Hyderabad 500 604, India.
J Mark PetrashDepartment of Ophthalmology, University of Colorado Denver, CO, USA. Electronic address: mark.petrash@ucdenver.edu.
University of Colorado Denver · USNational Institute of Nutrition · INRocky Mountain MS Center · US

Funding

MOLECULAR BIOLOGY OF ALDOSE REDUCTASE AND CATARACTR01EY005856 · NEI · WASHINGTON UNIVERSITY · PI PETRASH, JONATHAN MARK · 1988 to 2014
$6.8M
Novel Therapeutics Against Diabetic Eye DiseaseR01EY021498 · NEI · UNIVERSITY OF COLORADO DENVER · PI LABARBERA, DANIEL V., PETRASH, JONATHAN MARK · 2011 to 2015
$2.1M
Vision Research Training ProgramT35EY021455 · NEI · UNIVERSITY OF COLORADO DENVER · PI PETRASH, JONATHAN MARK, ROSS, RANDAL G · 2011 to 2015
$74k
MOLECULAR STUDIES OF ALDOSE REDUCTASE AND CATARACTR23EY005856 · NEI · EMORY UNIVERSITY · PI PETRASH, JONATHAN MARK · 1985 to 1987
–
MOLECULAR BIOLOGY OF ALDOSE REDUCTASE AND CATARACTR55EY005856 · NEI · WASHINGTON UNIVERSITY · PI PETRASH, JONATHAN MARK · 1991 to 1991
–
NEI NIH HHS EY005856NEI NIH HHS R01 EY005856NEI NIH HHS R01 EY021498NEI NIH HHS T35 EY021455
6 · The paper itself

Abstract

Aldose reductase (AR) is thought to play a role in the pathogenesis of diabetic eye diseases, including cataract and retinopathy. However, not all diabetics develop ocular complications. Paradoxically, some diabetics with poor metabolic control appear to be protected against retinopathy, while others with a history of excellent metabolic control develop severe complications. These observations indicate that one or more risk factors may influence the likelihood that an individual with diabetes will develop cataracts and/or retinopathy. We hypothesize that an elevated level of AR gene expression could confer higher risk for development of diabetic eye disease. To investigate this hypothesis, we examined the onset and severity of diabetes-induced cataract in transgenic mice, designated AR-TG, that were either heterozygous or homozygous for the human AR (AKR1B1) transgene construct. AR-TG mice homozygous for the transgene demonstrated a conditional cataract phenotype, whereby they developed lens vacuoles and cataract-associated structural changes only after induction of experimental diabetes; no such changes were observed in AR-TG heterozygotes or nontransgenic mice with or without experimental diabetes induction. We observed that nondiabetic AR-TG mice did not show lens structural changes even though they had lenticular sorbitol levels almost as high as the diabetic AR-TG lenses that showed early signs of cataract. Over-expression of AR led to increases in the ratio of activated to total levels of extracellular signal-regulated kinase (ERK1/2) and c-Jun N-terminal (JNK1/2), which are known to be involved in cell growth and apoptosis, respectively. After diabetes induction, AR-TG but not WT controls had decreased levels of phosphorylated as well as total ERK1/2 and JNK1/2 compared to their nondiabetic counterparts. These results indicate that high AR expression in the context of hyperglycemia and insulin deficiency may constitute a risk factor that could predispose the lens to disturbances in signaling through the ERK and JNK pathways and thereby alter the balance of cell growth and apoptosis that is critical to lens transparency and homeostasis.

Indexed as

Aldehyde ReductaseAnimalsApoptosisCataractDiabetes ComplicationsDiabetes Mellitus, ExperimentalGlucoseHumansHyperglycemiaInsulinLens, CrystallineMAP Kinase Signaling SystemMiceMice, Inbred C57BLMice, TransgenicRisk FactorsAldehyde ReductaseGlucoseInsulinSorbitolAKR1B1Aldose reductaseCataractDiabetes

Identifiers

PMID25541468
PMCPMC4414723
OpenAlexW2093984536

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.